Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) Sees Significant Drop in Short Interest
Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) Sees Significant Drop in Short Interest
Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 31,000 shares, a decline of 11.9% from the July 15th total of 35,200 shares. Based on an average daily trading volume, of 9,800 shares, the short-interest ratio is presently 3.2 days.
智能制药国际公司(场外交易代码：IPCIF-GET评级)(东京证券交易所代码：I)7月份空头股数股价大幅下跌。截至7月31日，空头股数共有3.1万股，较7月15日的3.52万股下降11.9%。以日均成交量9,800股计算，目前短息比率为3.2天。
Intellipharmaceutics International Price Performance
IntelliPharmPharmtics International价格表现
OTCMKTS IPCIF traded down $0.02 on Monday, hitting $0.09. 1,000 shares of the company were exchanged, compared to its average volume of 10,463. The firm has a market capitalization of $2.81 million, a P/E ratio of -0.31 and a beta of 1.67. The company's 50 day moving average price is $0.10 and its 200-day moving average price is $0.12. Intellipharmaceutics International has a twelve month low of $0.08 and a twelve month high of $0.30.
OTCMKTS IPCIF周一下跌0.02美元，触及0.09美元。该公司的股票成交量为1000股，而其平均成交量为10,463股。该公司的市值为281万美元，市盈率为-0.31，贝塔系数为1.67。该公司的50日移动均线价格为0.10美元，其200日移动均线价格为0.12美元。IntelliPharmPharmtics International的12个月低点为0.08美元，12个月高位为0.30美元。
Intellipharmaceutics International (OTCMKTS:IPCIF – Get Rating) (TSE:I) last released its quarterly earnings results on Thursday, July 21st. The company reported ($0.05) EPS for the quarter.
IntelliPharmPharmtics International(OTCMKTS：IPCIF-GET Rating)(东京证券交易所代码：I)最近一次发布季度收益报告是在7月21日星期四。该公司公布了该季度每股收益(0.05美元)。
Intellipharmaceutics International Company Profile
智能制药国际公司简介
Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
IntelliPharmPharmtics International Inc.是一家制药公司，在美国研究、开发和制造新型和仿制药的控释和靶向释放口服固体剂量药物。该公司在神经学、心血管、胃肠道、糖尿病和疼痛等不同治疗领域基于其获得专利的HyperMatrix技术开发各种药物输送系统、候选产品和一系列产品。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Intellipharmaceutics International (IPCIF)
- The Five Hottest Calls From The Q2 Earnings Season
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- The Institutions Trim Holdings Of High-Yielding Foot Locker, Inc
- 免费获取StockNews.com关于IntelliPharmPharmtics International(IPCIF)的研究报告
- 第二季度财报季最热门的五个电话
- 以下是一个简单的4只股票投资组合，它可以跑赢大盘
- AMC娱乐公司是在对猩猩采取快速行动吗？
- 以下是《降低通胀法案》如何提振电力库存
- 机构调整高收益Foot Locker，Inc.的控股
Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.
获得IntelliPharmPharmtics International Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对IntelliPharmPharmtics International和相关公司的最新新闻和分析师评级的每日简要摘要。
